Drugs / RO6807952
last change Jan 2012 re-read 2 minutes ago

RO6807952

Developed for
type 2 diabetes mellitus
Investigated by
Hoffmann-La Roche

Trials 2 · a red edge is where a trial was stopped

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT01358929 Apr → Sep 2011 type 2 diabetes mellitus Hoffmann-La Roche Completed No outcome recorded
Phase 21 trial
Phase 2 NCT01516476 Nov 2011 → Jan 2012 type 2 diabetes mellitus Hoffmann-La Roche Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as RO6807952 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01358929
1

NCT01516476

Route Subcutaneous “multiple weekly subcutaneous doses” NCT01358929